Table 1.
Demographic and clinical characteristics of participants.
| All Participants (n = 172) | Analysis Sample (n = 158) | |||||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| N | Mean (SD) or N | Range | N | Mean (SD) or N | Range | |||
| (%) | (%) | |||||||
| Age | 172 | 56.6 (8.4) | 36–78 | 158 | 56.6 (8.4) | 36–78 | ||
| Race | 172 | 158 | ||||||
| White | 159 (92.4%) | 146 (92.4%) | ||||||
| Black | 10 (5.8%) | 10 (6.3%) | ||||||
| Asian | 1 (0.6%) | 0 (0%) | ||||||
| Mixed | 2 (1.2%) | 2 (1.3%) | ||||||
| BMI, kg/m2 | 172 | 158 | ||||||
| <18.5 | 0 (0%) | 0 (0%) | ||||||
| Underweight | ||||||||
| 18.5–24.9 | 61 (35.5%) | 56 (35.4%) | ||||||
| Healthy | ||||||||
| 25–29.9 | 60 (34.9%) | 55 (34.8%) | ||||||
| Overweight | ||||||||
| > 29.9 Obese | 51 (29.7%) | 47 (29.7%) | ||||||
| Trunk fat, kg (DXA) | 172 | 15.7 (6.7) | 3.1–34.3 | 158 | 15.7 (6.7) | 3.1–34.3 | ||
| VO2peak, mL/(kg min) | 158 | 22.0 (5.3) | 10.2–33.6 | 158 | 22.0 (5.3) | 10.2–33.6 | ||
| Years since treatment | 172 | 3.5 (2.3) | 0.8–9.9 | 158 | 3.6 (2.3) | 0.8–9.9 | ||
| Chemotherapy treatment | 172 | 116 (67.4%) | 158 | 108 (68.4%) | ||||
| Radiation treatment | 172 | 105 (61.0%) | 158 | 94 (59.5%) | ||||
| Current Hormone therapy | 172 | 138 (80.2%) | 158 | 128 (81.0%) | ||||
| Cancer stage | 172 | 158 | ||||||
| Stage I | 81 (47.1%) | 75 (47.5%) | ||||||
| Stage II | 82 (47.7%) | 76 (48.1%) | ||||||
| Stage III | 9 (5.2%) | 7 (4.4%) | ||||||
| Any comorbidities | 171 | 22 (12.9%) | 158 | 20 (12.7%) | ||||
| CES-D score | ||||||||
| Visit 1 | 172 | 7.5 (6.8) | 0–37 | 158 | 7.6 (6.9) | 0–37 | ||
| Visit 2 | 163 | 7.7 (6.9) | 0–41 | 149 | 7.8 (7.0) | 0–41 | ||
| Energy/Fatigue* | ||||||||
| Visit 1 | 172 | 60.4 (18.8) | 10–90 | 158 | 60.9 (19.0) | 10–90 | ||
| Visit 2 | 163 | 61.7 (19.7) | 0–100 | 149 | 62.0 (19.8) | 0–100 | ||
| Fasting IL-6, pg/mL | ||||||||
| Visit 1 | 171 | 2.8 (6.1) | 0.4–78.4 | 157 | 2.9 (6.4) | 0.4–78.4 | ||
| Visit 2 | 163 | 2.8 (6.4) | 0.4–80.6 | 149 | 2.8 (6.7) | 0.5–80.6 | ||
| Fasting IL-1Ra, pg/mL | ||||||||
| Visit 1 | 171 | 542 (3 94) | 121 −1991 | 157 | 548 (386) | 121 −1991 | ||
| Visit 2 | 163 | 526 (3 69) | 143–2389 | 149 | 525 (342) | 143–1888 | ||
| Fasting WBC, K/uL | ||||||||
| Visit 1 | 169 | 5.1 (1.4) | 1.9–9.1 | 155 | 5.1 (1.4) | 1.9–9.1 | ||
| Visit 2 | 163 | 5.0 (1.3) | 1.7–10.5 | 149 | 5.0 (1.3) | 1.7–10.5 | ||
*
From SF-36 RAND Health Survey, higher is less fatigued.